Du är här


Novartis International AG: Novartis and Anne Geddes unveil inspirational eBook featuring meningitis survivors in honor of World Meningitis Day

Novartis International AG / Novartis and Anne Geddes unveil inspirational
eBook featuring meningitissurvivors in honor of World Meningitis Day .
Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is
solely responsible for the content of this announcement.
* Protecting Our Tomorrows: Portraits of Meningococcal Disease eBook features
15 survivors from around the world; eBook available for free download on

* Approximately 500,000 cases of meningococcal disease occur worldwide each
year, causing about 50,000 deaths; infants and adolescents most at

* Novartis is committed to working with patient groups and public health
officials to ensure every child at risk receives vaccination against this
devastating disease

Basel, April 23, 2014 -
Novartis, in partnership with world-renowned photographer Anne Geddes, the
Confederation of Meningitis Organisations (CoMO) and charities around the
world, has announced the publication of an eBook featuring inspirational
images of meningococcal disease survivors from across the globe who have
participated in theProtecting Our Tomorrows: Portraits of Meningococcal
campaign. This project aims to raise public awareness of a rare but
potentially deadly disease and the importance of vaccination in helping to
prevent the disease. The eBook will be available for free download
exclusively on iBooks®tomorrow, April 24, 2014, in honor of the sixth annual
World Meningitis Day, at the following link:bit.ly/1oEZumh.

"Through a series of what I believe are inspirational photographs of
meningococcal disease survivors and families impacted by the disease, this
project celebrates the survivors' triumphs and honors those who've tragically
lost their lives," said Ms. Geddes. "Over my 30-year career, there is not one
parent I have worked with who doesn't love their children, want to nurture
their children and protect their children. Through these images, I hope
parents feel empowered to understand the disease's impact and know the
options available to them."

"Through decades of research, Novartis has developed vaccines which helped to
significantly reduce the incidence of some of the most common and serious
strains of meningococcal disease across the world," said Andrin Oswald,
Division Head, Novartis Vaccines. "Much more can and should be done to make
sure every child at risk gets vaccinated. This is the mission of our company.
A mission that we try to fulfill to the best of our abilities and as
responsibly as we can, working together with the many patient groups,
physicians and public health officials who are as determined as we are."

Meningococcal disease is a sudden, aggressive and life-threatening disease,
with infants and adolescents at the greatest risk[3],[2]. Five main groups of
meningococcal bacteria (A, B, C, W135 and Y) cause virtually all cases of the
disease around the world, with serogroup B being the greatest cause in the
developed world[4],[5]. Novartis is a leader in developing innovative
vaccines, and is the only company with licensed vaccines for all five
serogroups including B.

The eBook is the culmination of a worldwide project launched in 2013, aiming
to raise awareness of this rare but aggressive disease that can leave its
victims with life-long complications, such as brain damage, learning
disabilities, hearing loss and limb loss[3],[6]. Ms. Geddes traveled the
world to meet the 15 project participants from eight countries (Australia,
Canada, Brazil, Germany, Ireland, Spain, the United Kingdom and the United
States) and to depict their resilience through their portraits. As global
project ambassador, Ms. Geddes has also worked to foster awareness and
encourage meningococcal disease education through meetings with journalists,
patient advocacy organizations and public officials. Throughout her journey,
she also chronicled her experiences on the campaign's Tumblr page

This press release contains expressed or implied forward-looking statements,
including statements that can be identified by terminology such as
"committed," "mission," or similar expressions. Such forward-looking
statements reflect the current views of the Group regarding future events,
and involve known and unknown risks, uncertainties and other factors that may
cause actual results to be materially different from any future results
expressed or implied by such statements. These expectations could be affected
by, among other things, risks and factors referred to in the Risk Factors
section of Novartis AG's current Form 20-F on file with the US Securities and
Exchange Commission. Novartis is providing the information in this press
release as of this date and does not undertake any obligation to update it in
the future.

About Novartis
Novartis provides innovative healthcare solutions that address the evolving
needs of patients and societies. Headquartered in Basel, Switzerland,
Novartis offers a diversified portfolio to best meet these needs: innovative
medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines
and diagnostic tools, over-the-counter and animal health products. Novartis
is the only global company with leading positions in these areas. In 2013,
the Group achieved net sales of USD 57.9 billion, while R&D throughout the
Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding
impairment and amortization charges). Novartis Group companies employ
approximately 136,000 full-time-equivalent associates and operate in more
than 140 countries around the world.
For more information, please visithttp://www.novartis.com.

Novartis is on Twitter. Sign up to follow @Novartis

[1] Kimmel, Sanford R. Using the tetravalent meningococcal
polysaccharide-protein conjugate vaccine in the prevention of meningococcal
disease. Journal of Therapeutics and Clinical Risk Management. Aug 2008;
4(4): 739-745.
[2] Cohn, A. et al. Changes in Neisseria meningitides Disease Epidemiology in
the United States, 1998-2007: Implications for Prevention of Meningococcal
Disease. Clinical Infectious Diseases 2010:50.
[3] Centers for Disease Control and Prevention. Epidemiology and Prevention of
Vaccine-Preventable Diseases (The Pink Book: Course Textbook). 12th Edition,
2nd printing. May 2012 update. Available
at:http://www.cdc.gov/vaccines/pubs/pinkbook/mening.html. Accessed April

[4] Immunization Action Coalition. Meningitis: Questions&Answers. Available
at:http://www.immunize.org/catg.d/p4210.pdf.Accessed April 2014.

[5] World Health Organization. Bacterial Meningitis. Available
at:http://apps.who.int/nuvi/meningitis/en/. Accessed April 2014.

[6] World Health Organization. Meningococcal Meningitis Fact Sheet
141.http://www.who.int/mediacentre/factsheets/fs141/en/. Accessed April 2014.

# # #

Novartis Media Relations

|Central media line : |
|+41 61 324 2200 |
|Eric Althoff Liz Power |
| |
| |
|Novartis Global Media Relations Novartis Global Media Relations |
| |
|+41 61 324 7999 (direct) +1 212 830-2466 (direct) |
|+41 79 593 4202 (mobile) +1 617 583 3015 (mobile) |
|eric.althoff@novartis.com elizabeth.power@novartis.com |

For Novartis multimedia content, please visitwww.thenewsmarket.com/Novartis
For questions about the site or required registration, please

Novartis Investor Relations

|Central phone: +41 61 324 7944 |
|Samir Shah +41 61 324 7944 North America: |
|Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 |
|Thomas Hungerbuehler +41 61 324 8425 Susan Donofrio +1 862 778 9257 |
|Isabella Zinck +41 61 324 7188 |
| |
|e-mail:investor.relations@novartis.com e-mail:investor.relations@novartis.com |
| |

Media release (PDF)


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novartis International AG via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.